Skip to main content
Journal cover image

Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.

Publication ,  Journal Article
Sperduto, PW; Mesko, S; Li, J; Cagney, D; Aizer, A; Lin, NU; Nesbit, E; Kruser, TJ; Chan, J; Braunstein, S; Lee, J; Kirkpatrick, JP; Breen, W ...
Published in: Neuro Oncol
September 29, 2020

BACKGROUND: Breast cancer treatment is based on estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, receptor status can be discordant from that at initial diagnosis. The purpose of this study was to determine the incidence of discordance and its effect on survival and subsequent treatment in patients with breast cancer brain metastases (BCBM). METHODS: A retrospective database of 316 patients who underwent craniotomy for BCBM between 2006 and 2017 was created. Discordance was considered present if the ER, PR, or HER2 status differed between the primary tumor and the BCBM. RESULTS: The overall receptor discordance rate was 132/316 (42%), and the subtype discordance rate was 100/316 (32%). Hormone receptors (HR, either ER or PR) were gained in 40/160 (25%) patients with HR-negative primary tumors. HER2 was gained in 22/173 (13%) patients with HER2-negative primary tumors. Subsequent treatment was not adjusted for most patients who gained receptors-nonetheless, median survival (MS) improved but did not reach statistical significance (HR, 17-28 mo, P = 0.12; HER2, 15-19 mo, P = 0.39). MS for patients who lost receptors was worse (HR, 27-18 mo, P = 0.02; HER2, 30-18 mo, P = 0.08). CONCLUSIONS: Receptor discordance between primary tumor and BCBM is common, adversely affects survival if receptors are lost, and represents a missed opportunity for use of effective treatments if receptors are gained. Receptor analysis of BCBM is indicated when clinically appropriate. Treatment should be adjusted accordingly. KEY POINTS: 1. Receptor discordance alters subtype in 32% of BCBM patients.2. The frequency of receptor gain for HR and HER2 was 25% and 13%, respectively.3. If receptors are lost, survival suffers. If receptors are gained, consider targeted treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

September 29, 2020

Volume

22

Issue

9

Start / End Page

1359 / 1367

Location

England

Related Subject Headings

  • Retrospective Studies
  • Receptors, Progesterone
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Oncology & Carcinogenesis
  • Humans
  • Estrogens
  • Breast Neoplasms
  • Brain Neoplasms
  • Biomarkers, Tumor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sperduto, P. W., Mesko, S., Li, J., Cagney, D., Aizer, A., Lin, N. U., … Mehta, M. P. (2020). Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro Oncol, 22(9), 1359–1367. https://doi.org/10.1093/neuonc/noaa025
Sperduto, Paul W., Shane Mesko, Jing Li, Daniel Cagney, Ayal Aizer, Nancy U. Lin, Eric Nesbit, et al. “Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.Neuro Oncol 22, no. 9 (September 29, 2020): 1359–67. https://doi.org/10.1093/neuonc/noaa025.
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro Oncol. 2020 Sep 29;22(9):1359–67.
Sperduto, Paul W., et al. “Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.Neuro Oncol, vol. 22, no. 9, Sept. 2020, pp. 1359–67. Pubmed, doi:10.1093/neuonc/noaa025.
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu C-C, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro Oncol. 2020 Sep 29;22(9):1359–1367.
Journal cover image

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

September 29, 2020

Volume

22

Issue

9

Start / End Page

1359 / 1367

Location

England

Related Subject Headings

  • Retrospective Studies
  • Receptors, Progesterone
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Oncology & Carcinogenesis
  • Humans
  • Estrogens
  • Breast Neoplasms
  • Brain Neoplasms
  • Biomarkers, Tumor